Abbvie Inc.

Apogenix Ag

Susan E Lappe

Ravi Chari

Jijie Gu

Supriya Gupta

Camellia Zamiri

Dominic J Ambrosi

Jonathan A Hickson

Yingchun Li

Louie Naumovski

Deanna L Haasch

Xianhua Cao

Meinolf Thiemann

Christian Gieffers

Oliver Hill

Fritz G Buchanan

Darren C Phillips

Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof

Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Single-chain trail-receptor agonist proteins

Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

Growing community of inventors

Riverwoods, IL, United States of America

Susan E Lappe